Jasper Therapeutics Inc (JSPR)

May 21, 2026

Jasper Therapeutics Announces Board Resignation and Committee Change - TipRanks

May 21, 2026

May 21, 2026

Christian Nolet resigns from Jasper Therapeutics board; Svetlana Lucas joins Audit Committee - TradingView

May 21, 2026

May 21, 2026

Jasper Therapeutics (NASDAQ: JSPR) reports director exit and audit change - Stock Titan

May 21, 2026

May 19, 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

May 19, 2026

May 18, 2026

Jasper Therapeutics, Inc.Class A Common Stock (NQ: JSPR - The Chronicle-Journal

May 18, 2026

May 18, 2026

Jasper Therapeutics stock maintains outperform rating at Citizens By Investing.com - Investing.com Canada

May 18, 2026

May 16, 2026

JSPR Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus

May 16, 2026

May 15, 2026

RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Hold Rating, Cuts Target Price to $3 - Moomoo

May 15, 2026

May 15, 2026

JSPR Maintained by RBC Capital -- Price Target Lowered to $3.00 - GuruFocus

May 15, 2026

May 15, 2026

RBC Cuts Price Target on Jasper Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk - Moomoo

May 15, 2026

May 15, 2026

TD Cowen Downgrades Jasper Therapeutics(JSPR.US) to Hold Rating - Moomoo

May 15, 2026

May 15, 2026

TD Cowen downgrades Jasper Therapeutics stock rating to Hold By Investing.com - Investing.com Canada

May 15, 2026

May 15, 2026

Jasper Therapeutics, Inc. Stock 12‑Month Price Target Cut to $9.08, Implies 847% Upside - TradingView

May 15, 2026

May 15, 2026

TD Cowen downgrades Jasper Therapeutics (JSPR) - MSN

May 15, 2026

May 14, 2026

Jasper Therapeutics shares rise 5% on clinical updates despite Q4 loss - MSN

May 14, 2026

May 14, 2026

Jasper Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2026

May 14, 2026

[10-Q] Jasper Therapeutics, Inc. Quarterly Earnings Report - Stock Titan

May 14, 2026

May 14, 2026

Jasper drug sees 67% complete response in CSU trial update - Stock Titan

May 14, 2026

May 14, 2026

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times

May 14, 2026

May 14, 2026

Jasper Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 14, 2026

May 14, 2026

Jasper Therapeutics (NASDAQ: JSPR) cuts Q1 2026 loss but flags funding risk - Stock Titan

May 14, 2026

May 14, 2026

Jasper Therapeutics (JSPR) price target decreased by 13.33% to 7.73 - MSN

May 14, 2026

May 12, 2026

Morgan Stanley units report sub‑5% stakes in Jasper Therapeutics (JSPR) - Stock Titan

May 12, 2026

May 12, 2026

TradingKey - TradingKey

May 12, 2026

May 10, 2026

The strategic priorities reflected in Jasper Therapeutics (JSPR) results | Q4 2025: Profit SurprisesRevenue Growth - Newser

May 10, 2026

May 08, 2026

[SCHEDULE 13G/A] Jasper Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan

May 08, 2026

May 08, 2026

Goldman Sachs (JSPR) joint 13G/A: 128,862 shares, 0.5% stake - Stock Titan

May 08, 2026

Apr 30, 2026

Executive pay and board changes at Jasper Therapeutics (JSPR) - Stock Titan

Apr 30, 2026

Apr 27, 2026

Jasper Shares Surge Following Encouraging Early Asthma Trial Data - MSN

Apr 27, 2026

Apr 21, 2026

12 Health Care Stocks Moving In Tuesday's After-Market SessionActuate Therapeutics (NASDAQ:ACTU), Celu - Benzinga

Apr 21, 2026

Apr 17, 2026

Why UBS started Jasper Therapeutics (JSPR) at neutral despite progress in briquilimab - MSN

Apr 17, 2026

Apr 16, 2026

Acute Myeloid Leukemia Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma, Syros Pharma, TC Biopharm - Barchart.com

Apr 16, 2026

Apr 09, 2026

Will Jasper Therapeutics (JSPR) Stock Fall Further | Price at $0.78, Up 10.73%Micro Trends - Newser

Apr 09, 2026

Apr 08, 2026

What is the biggest uncertainty for Jasper Therapeutics (JSPR) Stock | Price at $0.67, Up 0.87%Stop Loss Guidance - Newser

Apr 08, 2026

Apr 07, 2026

Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7 - Insider Monkey

Apr 07, 2026

Apr 07, 2026

JSPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 07, 2026

Apr 03, 2026

Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Alto Neuroscience, Inc. (ANRO) and Viridian Therapeutics (VRDN) - The Globe and Mail

Apr 03, 2026

Apr 02, 2026

12 Health Care Stocks Moving In Thursday's After-Market SessionBullfrog AI Hldgs (NASDAQ:BFRG), CDT Eq - Benzinga

Apr 02, 2026

Apr 02, 2026

Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway - The Globe and Mail

Apr 02, 2026

Apr 01, 2026

Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI - TipRanks

Apr 01, 2026

Apr 01, 2026

Citizens reiterates Jasper Therapeutics stock rating on CEO change By Investing.com - Investing.com Australia

Apr 01, 2026